Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients (CROSBI ID 177069)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Ročić, B ; Znaor, A ; Ročić, P ; Weber, D ; Vučić Lovrenčić, M
engleski
Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients
This study compares the effects of glibenclamide and creatine in type II diabetics. In a 14-day symmetrically randomized crossover trial recently detected type II diabetics received either creatine (3 g) or glibenclamide (3.5 mg) for five successive days, followed by two days of washout, and crossover to the opposite treatment. Glucose, insulin, c-peptide, and creatine were measured. Creatine and glibenclamide decreased glucose concentrations vs. basal glucose [15, 60, 90, 120, 180, and 240 min ; mol/l]: 12.60.83 vs. 12.20.56 vs. 12.10.57, 15.30.63 vs. 13.5 0.70a vs. 13.00.57a, 14.80.57 vs. 13.80.59a vs. 13.40.46a, 14.60.61 vs. 12.30.49b vs. 12.40.61a, 12.80.76 vs. 10.0 0.40c vs. 10.30.41c, and 11.40.67 vs. 8.30.40c vs. 8.50.36c ; (ap < 0.05 ; bp < 0.01 ; cp < 0.001 vs. basal glucose). Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 240min (p < 0.05 and p < 0.01). At the doses applied short-term treatment with creatine and glibenclamide elicits similar glucose lowering effects.
Creatine; glibenclamide; glucose; insulin; type II
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
161
2011.
objavljeno
0043-5341
1563-258X
10.1007/s10354-011-0905-7
Povezanost rada
Kliničke medicinske znanosti